Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rizatriptan + naproxen
- Development stage
- Unknown
- Lead developer
- Eurofarma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rizatriptan + naproxen is a combination of two pharmaceutical agents used for the acute treatment of migraine headaches. Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist (triptan) that works by causing vasoconstriction of intracranial blood vessels and inhibiting nociceptive neurotransmission in trigeminal pain pathways, thereby relieving migraine symptoms[1][3][5]. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes COX-1 and COX-2, reducing prostaglandin synthesis to provide analgesic and anti-inflammatory effects[6]. The combination targets both the vascular and inflammatory components of migraine pathophysiology. This dual mechanism may offer enhanced efficacy compared to either agent alone for some patients.
- Other names
- Rizatriptan-Naproxen (10/550 mg)rizatriptan benzoate + naproxen sodium
02
Targets
HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on rizatriptan + naproxen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rizatriptan + naproxen.